BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Correia ML, Haynes WG. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs 2005;10:643-60. [PMID: 16083333 DOI: 10.1517/14728214.10.3.643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35:4-16. [PMID: 22048570 DOI: 10.1038/hr.2011.173] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 8.7] [Reference Citation Analysis]
2 Sangwai M, Sardar S, Vavia P. Nanoemulsified orlistat-embedded multi-unit pellet system (MUPS) with improved dissolution and pancreatic lipase inhibition. Pharm Dev Technol 2014;19:31-41. [PMID: 23259606 DOI: 10.3109/10837450.2012.751404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
3 Engeli S, Jordan J. The endocannabinoid system: body weight and metabolic regulation. Clin Cornerstone 2006;8 Suppl 4:S24-35. [PMID: 17208664 DOI: 10.1016/s1098-3597(06)80041-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
4 Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7. [PMID: 17208644 DOI: 10.1016/S0140-6736(07)60033-6] [Cited by in Crossref: 488] [Cited by in F6Publishing: 145] [Article Influence: 32.5] [Reference Citation Analysis]